MedTrace Logo

Ondansetron Orodispersible Film for Vomiting Prevention in Pediatric Radiotherapy

NCT07217600 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-10-20

No results posted yet for this study

Summary

The goal of this study is to evaluate the antiemetic efficacy and drug safety of ondansetron orodispersible film in pediatric patients with malignant tumors who received moderate emetic risk radiation induced vomiting, and to formulate reasonable and effective clinical medication regimen for preventing vomiting caused by moderate emetic risk radiation in children with malignant tumor.

Conditions

  • Radiotherapy-induced Nausea and Vomiting (RINV)
  • Pediatric Cancer

Interventions

DRUG

Ondansetron orodispersible film once

Take ondansetron orodispersible film once 1-2 hours before each radiotherapy

DRUG

Ondansetron orodispersible film twice

Take ondansetron orodispersible film once before each radiotherapy , and once again 8 hours after the first dose.

Sponsors & Collaborators

  • Chongqing University Cancer Hospital

    lead OTHER

Principal Investigators

  • Yue Xie · Chongqing University Cancer Hospital, Chongqing, China

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
1 Year
Max Age
14 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-25
Primary Completion
2026-03-31
Completion
2026-04-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07217600 on ClinicalTrials.gov